MHRA Pauses Pathways Clinical Trial Following Safety Concerns for Children and Young People
Key Insights
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has paused the Pathways clinical trial following new concerns directly related to the wellbeing of children and young people participants.
Professor Jacob George (search) has been recused from further involvement in the trial as a precaution following the identification of social media posts made prior to his appointment.
The trial will only proceed if expert scientific and clinical evidence concludes it is both safe and necessary, with ongoing scientific dialogue between MHRA and King's College London as the trial sponsor.
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has paused the Pathways clinical trial following new safety concerns specifically related to the wellbeing of children and young people participants. The regulatory body announced that preparations for the trial have been suspended while clinical leaders work through these concerns with the trial sponsor, King's College London.
Regulatory Action and Safety Concerns
The MHRA emphasized that the decision reflects their unwavering commitment to participant safety. "With all clinical trials, the MHRA's top priority is the safety and wellbeing of the trial participants," an MHRA spokesperson stated. The agency noted that complex clinical trials are kept continuously under review, with active scientific dialogue maintained with trial sponsors.
The regulatory body has raised new concerns directly related to the wellbeing of children and young people involved in the study. These concerns have prompted immediate action, with scientific dialogue now following between the MHRA and King's College London as the trial sponsor.
Personnel Changes and Precautionary Measures
In a related development, Professor Jacob George (search) has been recused from further involvement in the Pathways clinical trial as a precautionary measure. This action follows the identification of social media posts made prior to his appointment to the trial. The MHRA confirmed this decision as part of their comprehensive approach to ensuring trial integrity and participant safety.
Expert Review Process
The MHRA has assembled world-class medical, scientific, and regulatory experts who work as a multidisciplinary team to provide evidence-based decisions on clinical trials. These experts will continue to meet with King's College London to work through the next steps constructively, according to the regulatory agency.
The trial's future depends entirely on the outcome of this expert review. Officials have made clear that the trial will only be allowed to proceed if the expert scientific and clinical evidence and advice conclude it is both safe and necessary for the pediatric population involved.
Commitment to Evidence-Based Decision Making
Authorities have maintained consistent red lines regarding the trial, emphasizing the paramount importance of ensuring the safety and wellbeing of children and young people involved while always being led by clinical evidence. The current pause allows for thorough interrogation of the evidence by clinicians and regulatory experts.
The MHRA's approach demonstrates the rigorous oversight applied to pediatric clinical trials, where additional safeguards are implemented to protect vulnerable populations. The agency's commitment to continuous review and evidence-based decision-making reflects international best practices in clinical trial regulation, particularly for studies involving children and young people.